- Regular Researcher, Cancer axis, CRCHUM
- Research member, Institut du cancer de Montréal
- Director of the Immunotherapy and Oncomicrobiome Laboratory
- Assistant Professor in Hemato-Oncology, Department of Medicine, Université de Montréal
Gut microbial fingerprint based on metagenomics profiling of patients stools to predict clinical resistance / response to anti-PD1/PD-L1/PD-L2 blockade in cancer.
- Meriem Messaoudene (PhD, post-doctoral fellow, firstname.lastname@example.org)
- Corentin Richard (PhD, post-doctoral fellow, email@example.com)
- Khoudia Diop (PhD, post-doctoral fellow, firstname.lastname@example.org)
- Myriam Benlaïfaoui (BSc, MSc, PhD student, email@example.com)
- Samia Hajem (BSc, PharmD, PhD student, firstname.lastname@example.org)
- Antoine Desilets (MD, master student, email@example.com)
- Wiam Belkaid (PhD, scientific coordinator, firstname.lastname@example.org)
- Florent Cauchois (BSc, research assistant, email@example.com)
- Concours Onco-Tech : nos équipes de recherche parmi les grands gagnants
- Le microbiote intestinal jouerait un rôle dans la réponse aux immunothérapies dans le cancer
- High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study.
- The Link Between the Gut Microbiome and Response to Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
- Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors.
- Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy.
- The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
Email address for applications
Dr. Bertrand Routy, MD, PhD, is Assistant Professor of Hemato-Oncology and Scientific Director of the Immunotherapy and Microbiome Laboratory at the Centre de recherche du Centre hospitalier de l’Université de Montréal. He received his MD from the Université de Montréal in 2009 and his diploma from the Internal Medicine program at McGill University. He then obtained a research fellowship at Princess Margaret Hospital-Toronto University. Following his medical training, he obtained a PhD in immuno-oncology at the Gustave Roussy Cancer Campus in Paris under the supervision of Professor Laurence Zitvogel in 2017.
Dr. Routy’s work includes understanding the deleterious impact of antibiotics on patients receiving immuno-blockers (IB). He has also helped establish that the composition of the gut microbiota has a major impact on the efficacy of BCIs in non-small cell lung cancer (NSCLC) and cancer. He has written and published several important articles in journals including Science, Immunity, Cell and Annals of Oncology. Dr. Routy’s research focuses on manipulating the gut microbiome in combination with immunotherapy to develop new therapies and biomarkers in thoracic oncology.